ARTICLE | Clinical News

Remicade infliximab regulatory update

August 30, 2010 7:00 AM UTC

The U.K.'s NICE issued guidance recommending use of Humira adalimumab, Enbrel etanercept and Remicade infliximab to treat adults with active and progressive psoriatic arthritis with 3 or more tender or swollen peripheral joints who did not respond to at least 2 DMARDs. The committee recommended starting therapy with the least expensive drug. The guidance is in line with a June final appraisal determination (FAD) (see BioCentury, June 14). ...